Patent Troll Legislation Would Alter PTO’s Validity Challenge Proceedings
This article was originally published in The Rose Sheet
Executive Summary
Legislation under consideration in both U.S. congressional houses seeks to address abusive patent litigation practices. At a recent Senate Judiciary Committee hearing, the Biotechnology Industry Organization expressed support for a Senate bill’s proposed revisions, including changes to the PTO’s increasingly popular inter partes review process, while arguing against provisions in a related House measure.
You may also be interested in...
Drug Firms Ask Senate For Narrow Patent Troll Bill
“One-size-fits-all” patent troll bill will harm innovators, Johnson & Johnson’s chief IP counsel tells Senate hearing.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.